Effective treatment for recurrent, disseminated prostate cancer is notably limited. We have developed adenoviral vectors with a prostate-specific two-step transcriptional amplification (TSTA) system that would express therapeutic genes at a robust level to target metastatic disease. The TSTA system employs the prostate-specific antigen (PSA) promoter/enhancer to drive a potent synthetic activator, which in turn activates the expression of the therapeutic gene. In this study, we explored different configurations of this bipartite system and discovered that physical separation of the two TSTA components into E1 and E3 regions of adenovirus was able to enhance androgen regulation and cell-discriminatory expression. The TSTA vectors that express imaging reporter genes were assessed by noninvasive imaging technologies in animal models. The improved selectivity of the E1E3 configured vector was reflected in silenced ectopic expression in the lung. Significantly, the enhanced specificity of the E1E3 vector enabled the detection of lung metastasis of prostate cancer. An E1E3 TSTA vector that expresses the herpes simplex virus thymidine kinase gene can effectively direct positron emission tomography (PET) imaging of the tumor. The prostate-targeted gene delivery vectors with robust and cellspecific expression capability will advance the development of safe and effective imaging guided therapy for recurrent metastatic stages of prostate cancer.
Introduction
Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in men in the United States. The American Cancer Society estimates that there will be approximately 219 000 new cases of prostate cancer in the United States in 2007 and approximately 27 000 expected deaths. 1 About onefourth of the patients that received treatment will suffer from disease recurrence detected by serum prostatespecific antigen (PSA). 2, 3 Hormonal therapy may induce short-term remission, but the refractory state eventually ensues. 4 Once metastases develop, effective therapeutic options become limited. Gene-based therapy is a promising possibility for disseminated disease. 5, 6 However, a potent and prostate-exclusive gene expression vehicle is required to achieve successful and effective in vivo gene therapy for recurrent or metastatic disease. 7 With that in mind, we employed the PSA promoter to engineer a gene expression system to target prostate cancer. [8] [9] [10] [11] [12] PSA, a serine protease purified from seminal plasma, 13 was first employed as a serum biomarker for prostate cancer in 1987. 14 To date, PSA remains the most important biomarker to guide the management of prostate cancer at all stages, at initial diagnosis or during treatment or upon disease recurrence. A key transcriptional regulator of PSA gene is the androgen receptor (AR), which plays a critical, indispensable role in the normal development of prostate gland as well as in prostate carcinogenesis. 15 The ubiquitous functional involvement of AR even extends to the lethal stage of prostate cancer. Detailed histological examination of metastatic lesions obtained from patients at the end stage of their disease revealed that AR and PSA are expressed, albeit at heterogenous level. 16, 17 Therefore, the use of PSA-based gene expression system is a rational strategy to target recurrent hormone refractory and metastatic prostate cancer.
The prostate-discriminating transcriptional activities of PSA promoter and enhancer elements have been extensively characterized. 7 However, a shortcoming of the native PSA promoter and enhancer is its weak transcriptional activity relative to constitutive viral promoters, such as CMV or SV40. Hence, our group and others have explored different strategies to augment the activity of the PSA promoter. 7 An early approach we undertook was to incorporate chimeric enhancer elements in cis, which elevated the native PSA promoter/ enhancer activity by nearly 20-fold while maintaining its prostate cell specificity. 9, 18 Upon further experimentation, a more effective approach, termed two-step transcriptional amplification (TSTA) was developed. TSTA achieved more than 800-fold enhancement over the native PSA promoter/enhancer. [10] [11] [12] The two components of TSTA system include (1) a strong synthetic activator (GAL4-VP16), which fuses the yeast GAL4 DNA binding domain with two copies of the herpes simplex virus VP16 activation domain, and (2) a GAL4-VP16-responsive transgene expression cassette. The prostate specificity of TSTA is governed by the use of the PSA promoter/enhancer to control expression of the GAL4-VP16 activator. By incorporating the intermediate amplification step, the TSTA system was able to achieve prostate-specific expression at a level higher than the viral CMV promoter, a benchmark widely used in the gene therapy and imaging fields. 11, 12 The TSTA system was incorporated into a recombinant adenoviral (Ad) vector to assess its imaging and therapeutic capabilities in relevant prostate tumor models. The Ad vector was chosen as the gene delivery vehicle of choice for in vivo applications because among many viral and non-viral vehicles developed to date, Ad remains the most widely used vehicle in clinical trials of cancer gene therapy. 19 The advantages of Ad include a very high titer production exceeding 10 12 infectious units per milliliter, its ability to transduce both dividing and nondividing cells of different tissue origins and its relative large capacity to accept exogenous genetic materials. 19 These properties are particularly beneficial to achieve robust, transient expression while mediating in vivo tumor-directed therapeutic effects. Indeed, when a TSTA Ad vector expressing the herpes simplex virus thymidine kinase (HSV-tk) gene (AdTSTA-sr39tk) was tested in preclinical, positron emission tomography (PET) imaging-guided suicide therapy paradigms, we observed a robust and tumor-specific PET signal, which correlated with effective tumoricidal effects. 8, 20 Studies from our group and others, to many of whom we have distributed the system, have demonstrated the utility of the TSTA method in augmenting the activity of a wide range of tissue-or cancer-specific promoters. 11, 12, [21] [22] [23] [24] [25] [26] [27] However, earlier findings suggest that optimal functioning of the bipartite TSTA system requires coordinate interactions between its two components without interference. 10 The adjacent, head-head arrangement of the PSA-GAL4-VP16 expression cassette and the GAL4-responsive reporter can lead to potential interference. In this study, we investigate different arrangements of the two TSTA components in relative large capacity of the Ad genome with the hope to develop a TSTA vector with enhanced regulated transcription. The strategies we undertook to diminish the potential interference of the two transcriptional regulatory regions included, the insertion of the chicken b-globin insulator sequence, 28 separating the two components with nearly 25 kb of intervening viral genome and arranging the orientation of the two transcriptional units in a diametrically opposing direction. We compared the activities of the TSTA vectors by their expression of firefly luciferase (fl) reporter gene, which can also be assessed by noninvasive bioluminescence imaging in animal models. We observed that among the different configurations, the construct in which the two TSTA components were inserted separately into E1 and E3 regions of adenovirus was able to achieve the tightest androgen regulation and best cell-discriminatory expression in vivo. The improved specificity of the E1E3 configured vector enabled it to detect lung metastasis in a preclinical model of prostate cancer. The gain in the specificity of the E1E3 TSTA vector is expected to augment the efficacy of imaging-guided gene therapy for prostate cancer.
Results

Different configurations of the TSTA system in Ad vectors
The results of our previous study indicated that functional separation of the two components of TSTA could achieve better cell-specific regulation and expression. 10 The close proximity of the two promoters in the original head-to-head (H-H) configuration (Figure 1 ) of TSTA Ad created a feed-forward loop that amplified the expression in minimal PSA expressing cells, leading to leaky background expression. The leaky expression is more prevalent in settings requiring a high multiplicity of infection (MOI), such as in animal studies. Hence, in this study we explored and tested different approaches to achieve functional separation of the bipartite TSTA system in an Ad vector ( Figure 1 ). The new constructs include (1) the insertion of the HS4 chicken b-globin insulator element 28 between the five GAL4 binding sites (5 Â GAL4) and PSE-BC promoter of the TSTA system (for example, AdTSTA-ins-fl); (2) switching the direction of two components to the tail-to-tail (T-T) configuration (for example, AdTSTA-TT-fl) and (3) the repositioning of the GAL4-VP16 transactivator component to the E3 region of adenovirus in order to physically separate it from the reporter component in E1 (for example, AdTSTA-E1E3-fl). We designed all of the newly configured TSTA Ad constructs to express the fl gene, such that their gene expression capabilities can be easily compared. We also generated a vector that expresses the HSV-tk gene in the most promising E1E3 configuration. The HSV-tk vector can be applied to suicide gene therapy and PET imaging of prostate cancer.
The different TSTA Ad configurations maintain proper regulation and prostate selectivity in cell culture models
The overall objective of molecular engineering of the TSTA Ad construct is to achieve optimal prostate tissue Configuration of prostate-specific adenoviral imaging vector M Sato et al selectivity and high level of expression. The function of the PSA promoter and its TSTA derivative is known to be highly dependent on the levels of androgen receptor and androgen in the tumor cells. 8, 10, 29 Hence, we first assayed the robustness of androgen-regulated transcriptional activity of our constructs. The activity of AdTSTA-fl was induced by androgen as low as 0.1 nM and it peaked at 10 nM. 8, 10 The new configured TSTA vectors reported here exhibited a similar androgen induction profile as the original AdTSTA-fl (data not shown). The inactivity of the reporter gene in the absence of androgen is a rigorous measure of stringent regulation of the TSTA system. Trace levels of androgen in the culture media or serum could activate the highly sensitive TSTA system. To obtain consistent measurement of the baseline activity in the absence of androgen, we measured the fl activity of all the constructs in the presence of the anti-androgen bicalutamide (Casodex, 10 mM).
To select the ideal configuration, we evaluated the androgen regulated expression and tissue selectivity (Figure 2 ) among the candidates. We first evaluated the insulator AdTSTA-ins-fl construct (Figure 1 ) by comparison with the original H-H configured AdTSTA-fl. The two vectors were added to an AR-and PSA-expressing human prostate cancer cell line LNCaP at an MOI ¼ 1. AdTSTA-ins-fl displayed a slight increase in peak, androgen-induced activity (with 10 nM synthetic androgen, R1881) and slightly diminished androgen null (with 10 mM Casodex) basal activity (Figure 2a) . The androgen induction, the ratio of the peak activity to the basal activity, is a good index of proper androgen-regulated activity. The androgen induction of AdTSTA-ins-fl was fourfold higher than AdTSTA-fl. This gain in androgen induction is modest compared the 25-fold gain observed for the E1E3 construct (Figure 2c ). Therefore, we decided not to evaluate this insulator construct further in this study. The compact contiguous nature of the insulated TSTA construct could be advantageous particularly in gene vectors where space constraint is a concern. These issues need to be explored in future studies.
We next compared the T-T and E1E3 configuration to the original AdTSTA-fl ( Figure 2b ). The peak activities in the presence of androgen of the three constructs were very similar, all within 20% higher (T-T) or lower (E1E3) than AdTSTA-fl (H-H). However, their basal activities in absence of androgen were significantly different ( Figure 2b ). AdTSTA-fl displayed the highest basal activity, followed by the T-T construct. Among the three constructs E1E3 showed the lowest basal activity: 20-fold lower than AdTSTA-fl. The lower basal activity of the constructs can significantly impact their androgen induction, which was calculated to be 2078-, 461-and 81-fold for E1E3, T-T and the original AdTSTA-fl, respectively ( Figure 2c ). The E1E3 vector also displayed a lower basal activity in CWR22Rv1, an androgen independent, AR-positive prostate cancer cell line. In the presence of 10 mM Casodex, the activity of AdTSTA-E1E3-fl was 30.5±2.7% of AdTSTA-fl in CWR22Rv1 cell line. In conclusion, the androgen regulation profile data indicate that the E1E3 is the most tightly regulated TSTA configuration.
We next compared the cell-selective expression of the E1E3 construct to AdTSTA-fl by measuring their expression level in three prostate cancer cell lines (LNCaP, LAPC-4 and CWR22Rv1) and two nonprostate cell lines (A549/human lung adenocarcinoma and HeLa/human 0 and 3 0 of an expression cassette, respectively. Except E1E3, all components were inserted into the multiple cloning sites of pShuttle in E1 region. In the E1E3 configuration, the reporter cassette is inserted in E1 region and the activator component is in E3 region. To accommodate the insertion of the activator component, pAdEasy-1 plasmid was modified to carry a cloning site in the E3 region (see Materials and methods).
Configuration of prostate-specific adenoviral imaging vector M Sato et al cervical carcinoma cells). LNCaP and LAPC-4 are androgen-dependent (AD) cell lines, and CWR22Rv1 is an androgen-independent (AI) cell line. [30] [31] [32] Although these three prostate cell lines all express AR, the androgen-stimulated activity of AdTSTA-fl in the cell lines was quite variable, spanning a 10-fold range. AR stimulation was determined to be most active in LNCaP and least active in CWR22Rv1. 8 AdTSTA-fl activity was negligible in the A549 cell line and murine lung tissue. 10 The tissue discriminatory activity of the TSTA Ad constructs was surveyed by plotting the activity in prostate cell lines over the two nonprostate lines. The differential expression ranged from 10-fold (CWR/A549, Figure 2d ) to nearly 166 000-fold (LNCaP/HeLa, Figure 2e ). Interestingly, the E1E3 construct exhibited greater prostate-selectivity over AdTSTA-fl in every case tested (Figures 2d and e) . A striking example is that the activity of AdTSTA-E1E3-fl was 166 000 times higher in LNCaP cell than in HeLa cells, while AdTSTA-fl displayed a 16 000-fold differential in the same paired cell lines.
In vivo prostate-directed activity of the TSTA Ad vectors
To evaluate the in vivo prostate-specific expression capability of the vectors, we injected 10 7 infectious plaque-forming units (pfu) of each vector into posterior lobes of the prostate gland of severe immunodeficiency disease (SCID) mice. The expression level of the TSTA vectors was monitored by repetitive optical bioluminescence imaging of the animals up to 28 days post injection. Interestingly, the highest signal on day 7 was observed in the animals that received AdTSTA-E1E3-fl, which was 100,000,000 10,000,000 1,000,000 100,000 Configuration of prostate-specific adenoviral imaging vector M Sato et al approximately 10-fold higher than the original AdTSTAfl or the T-T construct ( Figure 3 ). This finding was unexpected since the cell culture infection study showed that the E1E3 construct displayed lower androgenstimulated peak activity than the other two constructs (Figure 2b ). The three TSTA vectors exhibited slightly different expression kinetics during the 28-day duration of the experiment. The expression profile of AdTSTA-fl was relatively stable, while the AdTSTA-TT-fl-and AdTSTA-E1E3-fl-mediated expression followed a gradual decline. Although the T-T construct exhibited the highest activity in vitro, the expression level in vivo was in fact lowest among the three constructs throughout the course of the experiment. The results of this experiment highlight the point that assessment in cell culture models might not accurately reflect the in vivo activity.
Activity of TSTA constructs after systemic delivery in mice
Our past experience demonstrated that AdTSTA-fl was inactive in the liver 10, 20 despite the fact that liver is the dominant site of vector delivery following systemic administration. 33, 34 However, one of the reasons to improve the specific activity of AdTSTA-fl was that a weak signal was consistently observed in the lungs of the animals after intravenous administration of the vector. 10 To assess whether the gain we observed in cell-selective expression of the new TSTA vectors in cell culture models ( Figure 2 ) can be recapitulated in animal models, we administered the T-T, E1E3 and the original AdTSTA-fl into naive SCID mice via tail vein. Equivalent delivery of the three vectors was confirmed by real-time quantitative PCR of total DNA extracted from the livers harvested at the end of experiment. The amount of viral DNA that was delivered by the three viruses varied by only 1.16-fold.
The vector-mediated luciferase expression in the experimental subjects was monitored noninvasively over the 36-day duration of experiment by BLI. As shown in Figure 4 , the animals that received 10 7 pfu of AdTSTA-fl or AdTSTA-TT-fl exhibited significant optical signals in the chest, which steadily increased from day 6 onward and peaked on day 26 (see graph of Figure 4 ). In contrast, the same dose of AdTSTA-E1E3-fl did not generate a significant signal in the chest throughout the course of the experiment. A minimal discernable signal was observed when a 10-fold higher dose of E1E3 vector (10 8 pfu) was administered. per steradian. To confirm the origin of the bioluminescence signal in the chest, organs were isolated at the Configuration of prostate-specific adenoviral imaging vector M Sato et al endpoint of the study (day 36) and re-imaged ex vivo. As shown in Figure 4 (top), the source of luminescent signal was from the lung and not from the liver.
The application of AdTSTA-E1E3-fl to detect lung metastasis of prostate cancer Next, we asked whether the gain in cell selectivity of AdTSTA-E1E3-fl could be translated to improve a diagnostic imaging application in a relevant metastatic model of prostate cancer. Recently, several spontaneous metastatic models of human prostate cancer were developed in our group by the over-expression of prolymphangiogenic growth factor, VEGF-C. 35, 36 These tumors, implanted either subcutaneously or in the orthotopic murine prostatic gland, disseminate consistently from the primary tumor to draining lymph nodes and systemic sites, such as the lung. 35 In this study, we utilized the VEGF-C expressing LAPC-9 tumor cells 32, 36 to establish orthotopic tumors (Figure 5a ). The AR and PSA positive LAPC-9 tumor model confers robust TSTA vector-mediated expression 8, 29 and exhibits prominent CD31 + stained blood vasculature (Figure 5a ). In the represented sections, the tumor was observed to grow adjacent to normal prostatic glands (Figure 5a , upper right) and invading into a stroma region rich in blood vessels (arteries and veins), causing hemorrhage. These tumor-vascular interfaces might provide tumor cells the opportunity to gain access to circulation and initiate the metastatic process. AdTSTA-E1E3-fl (10 8 pfu) was injected via the tail vein into either naïve or LAPC-9 tumor-bearing mice, on day 21 after tumor implantation. BLI performed 3 days after vector administration revealed prominent signals in the chest of the tumorbearing mouse, which were 8-to 14-fold above the background signal (6.27 Â 10 3 photons s À1 cm À2 per steradian) observed in the naïve animal (Figure 5b ). When the lung lobes from the same animal were harvested and re-imaged ex vivo, an isolated focus of bioluminescent signal was detected at the periphery of the isolated lung lobe (Figure 5c ). Detailed histological examination revealed the presence of a cluster of metastatic tumor cells in the same peripheral region of the lung (Figure 5d ).
The application of the HSV-tk expressing TSTA vector in PET imaging
It is important to develop molecular imaging approaches that can be applied in clinical settings for advanced prostate cancer. PET is a radionuclide functional imaging modality that enables 3D signal localization in human as well as small animals. We have generated the TSTA vector that expresses the HSV-tk variant gene sr39tk in the original H-H configuration, and we showed that this AdTSTA-sr39tk can function effectively both as a prostate-specific PET imaging and suicide gene therapy Figure 4 Restricted expression of two-step transcriptional amplification (TSTA) vectors in the naIve animals. To assess the cell selectivity of TSTA adenoviral (Ad) vectors in mice, 10 7 pfu of each vector was injected into the tail vein. Luciferase activity was monitored by optical imaging through day 36. Animals were killed on day 36 and the imaging of the livers and lungs was performed ex vivo. Both AdTSTA-fl and AdTSTA-TT-fl displayed a considerable level of expression in the chest region, which is derived from the lungs. Nonsignificant, background signal was observed from mice that received 10 7 pfu of AdTSTA-E1E3-fl. Dotted line, background luminescence levels.
Configuration of prostate-specific adenoviral imaging vector M Sato et al vector. 8, 20 In this study, we constructed the E1E3 configured sr39tk expressing vector (AdTSTA-E1E3-sr39tk) and compared its activity to the original H-H AdTSTA-sr39tk. The sr39tk protein expression directed by AdTSTA-sr39tk and AdTSTA-E1E3-sr39tk was comparable in LNCaP cell line (Figure 6a ). LAPC-9 human prostate tumors were established on each shoulder of an animal. To compare the PET imaging capability of AdTSTA-sr39tk and AdTSTA-E1E3-sr39tk, 10 9 pfu of each vector was injected into a tumor when it reached 400-500 mm 3 . Seven days later, microPET imaging was performed using [ 18 F]-FHBG as tracer. As shown in Figure 6b , AdTSTA-sr39tk and AdTSTA-E1E3-sr39tk produced comparable PET signals. The ratio between two vectors (AdTSTA-sr39tk/AdTSTA-E1E3-sr39tk) was 1.03 and 0.99 in left and right mouses, respectively. This result suggests that the level of HSV-sr39tk gene expression mediated by the two vectors was comparable in the tumors. We anticipate AdTSTA-E1E3-sr39tk to be efficacious in diagnostic imaging or in image-guided gene therapy for prostate cancer.
Discussion
The efficacy of prostate cancer gene therapy depends on the ability to direct efficient in vivo gene expression in a cancer cell-restricted manner. In addition, being able to non-invasively monitor the gene delivery and expression processes in the subjects during treatment will be very helpful toward advancing gene therapy. With this concept in mind, we have developed the novel prostate specific TSTA Ad vectors to express imaging and/or therapeutic reporters. Two studies have demonstrated the utility of the TSTA Ad vectors in a PET imagingguided suicide gene therapy in preclinical prostate cancer models. 8, 20 Although these studies were pivotal in establishing the TSTA gene therapy approach as a viable clinical tool for prostate cancer, challenges remain in refining the optimal regulation of the system. In the current study, we have systematically evaluated and improved upon the TSTA regulatory mechanism, resulting in enhanced specificity for AR-and PSA-expressing prostate cancer cells. The improved cell-restricted gene expression of TSTA-directed prostate cancer gene therapy is likely to increase safety and therapeutic indices by reducing immunogenicity 37 and limiting adverse side effects. 7 The regulation of gene expression within the TSTA system depends on the configuration of the activator and effector components. Expression efficiency of the system benefits greatly from engineering the activator and effector components within the same Ad vector (single system), 10 rather than in separate adenoviruses (separate system). Therefore, the relative placement of the activator relative to the effector within the single adenovirus genome can be a critical factor. Since the highest TSTA expression was observed with the TSTA plasmid construct configured with the activator and effector components in the head-to-head orientation, 11 the first 
Configuration of prostate-specific adenoviral imaging vector M Sato et al
Ad vector (AdTSTA-fl) was created in the same orientation. 10 However, unlike the separate system, the single head to head orientation produced a higher basal activity in androgen-depleted conditions. We postulate that this effect could be due to the close proximity of the PSA promoter and the potent VP16 enhancer element in the head-to-head configuration, in essence creating a feedforward loop. Hence, in this study, we investigated three molecular approaches to functionally separate the activator and enhancer elements. These approaches are as follows: (1) inserting a HS4 chicken b-globin 500-bp insulator sequence between the activator and reporter components (AdTSTA-ins-fl, or insulated); (2) reversing the orientation of the TSTA components (AdTSTA-TT-fl or tail-to-tail) 38, 39 and (3) placing the two components within different regions of Ad genome (deleted E1 and deleted E3 regions), spaced 25-kb apart (AdTSTA-E1E3-fl or E1E3).
In the present study, AdTSTA-E1E3-fl exhibited significant improvements in androgen regulation and cell-specific expression (Figures 2b, d and e) . However, based on the same analyses in cell culture, the maximal activity of E1E3 vector is approximately twofold lower than the original AdTSTA-fl or AdTSTA-TT-fl in LNCaP cells (Figure 2b) . Hence, we were pleasantly surprised to find that AdTSTA-E1E3-fl displayed significantly higher prostate expression (more than 10-fold) in vivo compared to the other two vectors. Potential explanations for this discrepancy could be that the native androgen environment in the murine prostate favors the proper transcriptional regulation of the E1E3 TSTA within the Ad context. Alternatively, the AR axis in mouse prostate cells could respond differently compared to human cell lines to the chimeric PSA promoter utilized in the TSTA vector.
In cell culture experiments, AdTSTA-E1E3-fl displayed the highest androgen induction and cell-specific transgene expression. For example, in LNCaP cells, the insulated, tail-to-tail, and E1E3 configurations of the TSTA vectors displayed a reduced baseline activity (39, 21 and 3%, respectively) compared to that of the head-tohead AdTSTA-fl vector. Consequently, androgen induction was the highest (2078-fold) with E1E3, followed by tail-to-tail (461-fold), and insulated (239-fold) compared to head-to-head parental AdTSTA-fl (only 81-fold). We also showed that E1E3 construct was able to achieve 166 000 times higher expression in LNCaP prostate cancer cells than in nonprostate (HeLa) cells, which is 10-fold more discriminating than AdTSTA-fl. These benefits of the E1E3 configuration revealed by the in vitro experiments corresponded very well with its activity in animal models.
The exquisite specificity of the E1E3 vector was revealed by comparing the intravenous administration of 10 7 pfu of three vectors (that is, AdTSTA-fl, AdTSTA-TT-fl and AdTSTA-E1E3-fl) into naive SCID mice. A low but significant level of signal from the lungs was observed in the AdTSTA-fl-or AdTSTA-TT-fl-injected animals, starting at one-week post injection (Figure 4 ). On the other hand, a negligible background level of signal was observed from the cohort that received AdTSTA-E1E3-fl. Even when a 10-fold higher dose (10 8 pfu) was administered, the lung signals were still lower than the level observed in AdTSTA-fl and AdTSTA-TT-fl (Figure 4 ). Most interestingly, the significant gain in specificity of AdTSTA-E1E3-fl has enabled the effective detection of lung micrometastasis in an orthotopic human prostate cancer xenograft model ( Figure 5 ). The ability to mediate specific gene expression and therapy in small metastatic lesions could have a significant impact on disease progression and long-term disease-free survival of prostate cancer patients. 40 This is a task that is seldom accomplished due to the unfavorable biodistribution of Ad vector resulting in the great majority of the virus being sequestered in the liver after systemic administration. 34 However, our experience indicates that the close proximity of small lung metastatic foci to the high density of lung capillaries could facilitate Ad-mediated gene transfer to the metastases. 6, 18 To translate our TSTA vector technology to image metastasis in the clinics, a high-energy radionuclide imaging approach will be needed. PET is a quantitative clinical imaging modality currently employed in oncology. Specifically, HSV-tk and its potent variant sr39tk gene have been widely used as PET imaging reporter genes. 41 We have previously shown that the TSTA Ad vector carrying sr39tk gene, AdTSTA-sr39tk, could achieve PET imaging in advanced stage androgenindependent human prostate tumors. 8 In this study, we generated the sr39tk-expressing vector in the E1E3 configuration. The resultant AdTSTA-E1E3-sr39tk achieved effective PET imaging signals at levels similar 9 pfu of AdTSTA-sr39tk and AdTSTA-E1E3-sr39tk was injected into LAPC-9 tumor xenografts on left and right shoulders, respectively. Image scanning was performed 7 days after injection using [
18 F]-FHBG as a radioactive tracer. Sequential images of micro-PET and micro-CT were combined.
Configuration of prostate-specific adenoviral imaging vector M Sato et al to the parental head-to-head AdTSTA-sr39tk in human prostate tumors ( Figure 6 ). Optimal regulation of a two-tiered gene expression system as achieved by the E1E3 configuration could be extended to a variety of applications. For instance, systems with a tetracycline-dependent transcriptional switch, steroid-dependent regulation, heat-or metalinducible systems, and small molecule-triggered systems all involve a two-step regulation strategy. [42] [43] [44] Moreover, other tissue-or tumor-specific promoters besides the PSA promoter can be employed to drive the TSTA system toward cancer-targeted gene therapy. Successful applications include PPT (a combination of a prostatespecific PSMA enhancer and the TARP promoter), 21 the midkine promoter, 22 VEGF promoter, 26 carcinoembryonic antigen promoter 24 and the pancreas-specific CCKAR (cholecystokinin type A receptor) promoter. 27 Findings from this report could be used to augment the activities of these systems as well. Collectively, the results of our study support the idea that the E1E3 configured TSTA vectors are promising candidates to engineer future clinical tools to manage metastatic prostate cancer. By reducing the basal activity, enhancing the activation and maintaining the robust level of expression of the original TSTA Ad vector, the E1E3 configuration will enable safer and more efficient targeted diagnostic and therapeutic strategies for prostate cancer and other types of cancers.
Materials and methods
Adenovirus constructs
All the Ad vectors were constructed based on the AdEasy system. 45 The virus was grown on 293 cells, purified on a CsCl gradient and titered by plaque formation assays on 293 monolayers. Viruses are stored in 10 mM Tris-HCl, 1 mM MgCl 2 and 10% glycerol at À80 1C until use. The head-to-head configuration of AdTSTA-fl and AdTSTA-sr39tk was constructed as previously described. 8, 29 The head-to-head with insulator construct was constructed by inserting the 610-bp chicken b-globin HS4 insulator element into Asp718I site in pTSTA-fl. 46 The resultant plasmid pTSTA-ins-fl was then digested with NotI and SalI to excise out the TSTA fragment with insulator. The fragment was then inserted into the pShuttle plasmid. The tail-to-tail configuration of the TSTA-fl was constructed as follows. Two NotI sites flanking BCVP2 cassette in PBCVP2G5-L 11 were utilized to switch orientation followed by removing three NotI sites to create unique site in the vector. G5-fl cassette was flipped by utilizing three ClaI sites franking the cassette. Resultant pTSTA-TT-fl was then digested and cloned into pShuttle using NotI and Asp718I.
The construction of the E1E3 configuration was initiated by the modification of pAdEasy-1 plasmid. The 1.4 kb of NdeI-SpeI fragment encompassing MCS in pAB26 (Microbix Biosystems, Inc., Toronto, Ontario, Canada) was excised out and ligated to 32.1 kb fragment of pAdEasy-1 with a combination of complete and partial digestion of SpeI and NdeI, respectively. To construct the adenovirus backbone plasmid carrying the activator component of the TSTA system, PSEBC-VP2 fragment derived from pShuttleBCVP2 (2Spe) was inserted into XbaI site in E3 region of resultant pAdNUEZ plasmid and named pAdNUEZBCVP2. The construction of pAdTSTA-E1E3-fl and pAdTSTA-E1E3-sr39tk is similar to that of pAdTSTA-fl. 8, 29 Of note, the Ad vector AdTSTA-fl in this paper is equivalent to AdTSTA-FL in previous reports from our group.
Cell culture and infection studies
The human prostate cancer cell lines, LNCaP and CWR22Rv1 were grown in RPMI-1640 (Mediatech, Herndon, VA, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S) solution. Iscove's modified Dulbecco's modified Eagle's medium (DMEM) with 10% FBS and 1% P/S was used for LAPC-4 cells. HeLa and A549 cells were cultured in RPMI-1640 with 10% FBS and 1% P/S. For luciferase assays, the cultured cells were plated onto 24-well plates at 5 Â 10 4 cells per well on the day before infection, and cells were counted at the day of infection to calculate MOI. For prostate cell lines, 10% charcoal-stripped serum was used instead of FBS. The cells were infected with respective Ad vector at MOI ¼ 1. Following infection, the synthetic androgen methylenetrienolone (R1881; NEN Life Science Products, Boston, MA, USA) or antiandrogen bicalutamide (Casodex) was added to samples as indicated. At 48 h post infection, the cells were harvested and lysed, using passive lysis buffer (Promega, Madison, WI, USA). Levels of luciferase activity were measured according to the manufacturer's instructions (Promega), using a luminometer (Berthold Detection Systems, Pforzheim, Germany) with a 10-s integration time. Each value was calculated as the average of triplicate samples.
Western analysis
LNCaP cells were infected with either AdTSTA-E1E3-fl or AdTSTA-fl at MOI ¼ 1, 2, 4 or 8. Following the infection, cells were incubated with either 10 mM Casodex or 10 nM R1881. Two days after infection, cells were harvested and subjected to SDS-PAGE (Invitrogen, Carlsbad, CA, USA). Proteins were transferred and the membrane was used for western analysis. Using anti-HSV-tk polyclonal antibody (gift from Dr Margaret Black in University of Washington), HRP-conjugated secondary antibody and chemiluminescence (Roche Diagnostics, Indianapolis, IN, USA), TK is visualized.
Animal experiments with optical and mPET imaging
Animal care and procedures were performed in accordance with the University of California Animal Research Committee guidelines. Male SCID mice, aged 10-12 weeks, were obtained from Taconic Farms (Germantown, NY, USA). For optical imaging, 10 7 pfu of the respective vector was injected to either posterior lobes of the prostate gland or systemically via tail vein. In vivo luciferase expression was monitored sequentially using a cooled IVIS CCD camera (Xenogen, Alameda, CA, USA). For each imaging session, the mice were anesthetized with ketamine/xylazine (4:1), given the D-luciferin substrate (200 ml of 150 mg kg À1 in PBS) intraperitoneally, and imaged after a 20-min incubation. Images were analyzed with IGOR-PRO Living Image Software, as described. 10, 47 For the mice injected systemically, the animals were killed on day 36 and subjected to the imaging of the livers and lungs ex vivo.
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For microPET imaging, 10 9 pfu (B30 ml) of AdTSTAsr39tk or AdTSTA-E1E3-sr39tk was injected into LAPC-9 tumor grafted in the left and right upper chest of the SCID mice, respectively. PET imaging was performed on day 7 using B200 mCi of [ 18 F]-FHBG substrate (specific activity 5-10 Ci mmol
À1
) that was administered via the tail vein. After 1 h of uptake time, mice were given inhalation isoflurane anesthesia, placed in a prone position and imaged for 20 min in the microPET scanner (Concorde Microsystems, Knoxville, TN, USA). Images were reconstructed using a filtered back projection reconstruction algorithm. MicroCT (Imtek Inc., Knoxville, TN, USA) was performed for the same animal sequentially, and images were overlapped using the AMIDE software. 48 
Immunohistochemistry
All tissues were fixed in 3% paraformaldehyde, paraffin embedded and sectioned at 5-mm thickness. After depariffinizing and rehydrating, sections were stained in hemotoxylin (0.2%) and eosin (0.25%). Some sections were also stained separately with a CD31 antibody as described previously. 35 
